Cox regression analysis for inhibitor development by NNA presence
| Adjustment variable . | All inhibitors . | High-titer inhibitor . | ||
|---|---|---|---|---|
| HR . | 95% CI . | HR . | 95% CI . | |
| Crude unadjusted model | 1.83 | 0.84-3.99 | 2.74 | 1.23-6.12 |
| Age at screening | 1.91 | 0.85-4.26 | 2.75 | 1.20-6.32 |
| Mutation | 2.33 | 1.05-5.15 | 3.53 | 1.56-8.00 |
| FVIII antigen level | 1.73 | 0.79-3.78 | 2.95 | 1.32-6.60 |
| Countries of enrollment | 2.36 | 1.03-5.42 | 3.91 | 1.62-9.44 |
| Familial history of inhibitor | 1.96 | 0.89-4.29 | 3.03 | 1.35-6.81 |
| Treatment arm | 1.73 | 0.79-3.78 | 2.61 | 1.17-5.84 |
| Exposure to blood components | 1.75 | 0.80-3.86 | 2.75 | 1.22-6.22 |
| Mutation, countries of enrollment | 3.62 | 1.49-9.42 | 5.76 | 2.17-15.26 |
| Adjustment variable . | All inhibitors . | High-titer inhibitor . | ||
|---|---|---|---|---|
| HR . | 95% CI . | HR . | 95% CI . | |
| Crude unadjusted model | 1.83 | 0.84-3.99 | 2.74 | 1.23-6.12 |
| Age at screening | 1.91 | 0.85-4.26 | 2.75 | 1.20-6.32 |
| Mutation | 2.33 | 1.05-5.15 | 3.53 | 1.56-8.00 |
| FVIII antigen level | 1.73 | 0.79-3.78 | 2.95 | 1.32-6.60 |
| Countries of enrollment | 2.36 | 1.03-5.42 | 3.91 | 1.62-9.44 |
| Familial history of inhibitor | 1.96 | 0.89-4.29 | 3.03 | 1.35-6.81 |
| Treatment arm | 1.73 | 0.79-3.78 | 2.61 | 1.17-5.84 |
| Exposure to blood components | 1.75 | 0.80-3.86 | 2.75 | 1.22-6.22 |
| Mutation, countries of enrollment | 3.62 | 1.49-9.42 | 5.76 | 2.17-15.26 |
HR compares the risk of inhibitor development among those with NNA at screening vs those without. Adjustments in multivariable Cox models were each performed individually.